FH is an inclusion eligibility criterion in 2 clinical trials for papillary renal cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FH status and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for papillary renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 status and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

IDH2 is an inclusion eligibility criterion in 1 clinical trial for papillary renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH2 status and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KRAS is an inclusion eligibility criterion in 1 clinical trial for papillary renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KRAS status and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MET is an inclusion eligibility criterion in 1 clinical trial for papillary renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and papillary renal cell carcinoma as inclusion criteria, 1 is phase 3 (1 open) [3].

MYC is an inclusion eligibility criterion in 1 clinical trial for papillary renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SDHA is an inclusion eligibility criterion in 1 clinical trial for papillary renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SDHA status and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SDHB is an inclusion eligibility criterion in 2 clinical trials for papillary renal cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain SDHB status and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

SDHC is an inclusion eligibility criterion in 1 clinical trial for papillary renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SDHC status and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SDHD is an inclusion eligibility criterion in 1 clinical trial for papillary renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SDHD status and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

TFE3 is an inclusion eligibility criterion in 2 clinical trials for papillary renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TFE3 status and papillary renal cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

TSC1 is an inclusion eligibility criterion in 1 clinical trial for papillary renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and papillary renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].